{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T15:54:41Z","timestamp":1794498881538,"version":"4.9.1"},"reference-count":46,"publisher":"American Medical Association (AMA)","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2024,10,15]]},"abstract":"<jats:sec id=\"ab-joi240053-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Plasma biomarkers show promise for identifying Alzheimer disease (AD) neuropathology and neurodegeneration, but additional examination among diverse populations and throughout the life course is needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-joi240053-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess temporal plasma biomarker changes and their association with all-cause dementia, overall and among subgroups of community-dwelling adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-joi240053-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>In 1525 participants from the US-based Atherosclerosis Risk in Communities (ARIC) study, plasma biomarkers were measured using stored specimens collected in midlife (1993-1995, mean age 58.3 years) and late life (2011-2013, mean age 76.0 years; followed up to 2016-2019, mean age 80.7 years). Midlife risk factors (hypertension, diabetes, lipids, coronary heart disease, cigarette use, and physical activity) were assessed for their associations with change in plasma biomarkers over time. The associations of biomarkers with incident all-cause dementia were evaluated in a subpopulation (n\u2009=\u20091339) who were dementia-free in 2011-2013 and had biomarker measurements in 1993-1995 and 2011-2013.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-joi240053-7\">\n                    <jats:title>Exposure<\/jats:title>\n                    <jats:p>Plasma biomarkers of amyloid-\u03b2 42 to amyloid-\u03b2 40 (A\u03b242:A\u03b240) ratio, phosphorylated tau at threonine 181 (p-tau181), neurofilament light (NfL), and glial fibrillary acidic protein (GFAP) were measured using the Quanterix Simoa platform.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-joi240053-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Incident all-cause dementia was ascertained from January 1, 2012, through December 31, 2019, from neuropsychological assessments, semiannual participant or informant contact, and medical record surveillance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-joi240053-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 1525 participants (mean age, 58.3 [SD, 5.1] years), 914 participants (59.9%) were women, and 394 participants (25.8%) were Black. A total of 252 participants (16.5%) developed dementia. Decreasing A\u03b242:A\u03b240 ratio and increasing p-tau181, NfL, and GFAP were observed from midlife to late life, with more rapid biomarker changes among participants carrying the apolipoprotein E epsilon 4 (\n                      <jats:italic>APOE<\/jats:italic>\n                      \u03b54) allele. Midlife hypertension was associated with a 0.15-SD faster NfL increase and a 0.08-SD faster GFAP increase per decade; estimates for midlife diabetes were a 0.11-SD faster for NfL and 0.15-SD faster for GFAP. Only AD-specific biomarkers in midlife demonstrated long-term associations with late-life dementia (hazard ratio per SD lower A\u03b242:A\u03b240 ratio, 1.11; 95% CI, 1.02-1.21; per SD higher p-tau181, 1.15; 95% CI, 1.06-1.25). All plasma biomarkers in late life had statistically significant associations with late-life dementia, with NfL demonstrating the largest association (1.92; 95% CI, 1.72-2.14).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-joi240053-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Plasma biomarkers of AD neuropathology, neuronal injury, and astrogliosis increase with age and are associated with known dementia risk factors. AD-specific biomarkers\u2019 association with dementia starts in midlife whereas late-life measures of AD, neuronal injury, and astrogliosis biomarkers are all associated with dementia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jama.2024.6619","type":"journal-article","created":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T07:30:43Z","timestamp":1722151843000},"page":"1258","source":"Crossref","is-referenced-by-count":92,"title":["Changes in Alzheimer Disease Blood Biomarkers and Associations With Incident All-Cause Dementia"],"prefix":"10.1001","volume":"332","author":[{"given":"Yifei","family":"Lu","sequence":"first","affiliation":[{"name":"Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Russell","family":"Pike","sequence":"additional","affiliation":[{"name":"Division of Epidemiology, Department of Population Health, New York University Grossman School of Medicine, New York"},{"name":"Optimal Aging Institute, New York University Grossman School of Medicine, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keenan A.","family":"Walker","sequence":"additional","affiliation":[{"name":"Laboratory of Behavioral Neuroscience, National Institute on Aging Intramural Research Program, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Department of Medicine, MIND Center, University of Mississippi Medical Center, Jackson"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharat","family":"Thyagarajan","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle M.","family":"Mielke","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Prevention, Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela L.","family":"Lutsey","sequence":"additional","affiliation":[{"name":"Division of Epidemiology and Community Health, University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Knopman","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca F.","family":"Gottesman","sequence":"additional","affiliation":[{"name":"National Institute of Neurological Disorders and Stroke Intramural Research Program, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Richey","family":"Sharrett","sequence":"additional","affiliation":[{"name":"Department of Medicine, MIND Center, University of Mississippi Medical Center, Jackson"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Coresh","sequence":"additional","affiliation":[{"name":"Division of Epidemiology, Department of Population Health, New York University Grossman School of Medicine, New York"},{"name":"Optimal Aging Institute, New York University Grossman School of Medicine, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas H.","family":"Mosley","sequence":"additional","affiliation":[{"name":"Department of Medicine, MIND Center, University of Mississippi Medical Center, Jackson"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Palta","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of North Carolina at Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"joi240053r1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","article-title":"Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation.","volume":"21","author":"Teunissen","year":"2022","journal-title":"Lancet Neurol"},{"issue":"10","key":"joi240053r2","doi-asserted-by":"publisher","first-page":"4335","DOI":"10.1002\/alz.13157","article-title":"Longitudinal changes in Alzheimer\u2019s-related plasma biomarkers and brain amyloid.","volume":"19","author":"Bilgel","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"11","key":"joi240053r3","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1093\/brain\/awaa286","article-title":"Longitudinal plasma p-tau217 is increased in early stages of Alzheimer\u2019s disease.","volume":"143","author":"Mattsson-Carlgren","year":"2020","journal-title":"Brain"},{"issue":"4","key":"joi240053r4","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.3233\/JAD-221287","article-title":"Associations of midlife lifestyle and health factors with long-term changes in blood-based biomarkers of Alzheimer\u2019s disease and neurodegeneration.","volume":"94","author":"Merten","year":"2023","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"joi240053r5","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1001\/jamaneurol.2020.4986","article-title":"Longitudinal associations of blood phosphorylated tau181 and neurofilament light chain with neurodegeneration in Alzheimer disease.","volume":"78","author":"Moscoso","year":"2021","journal-title":"JAMA Neurol"},{"issue":"8","key":"joi240053r6","doi-asserted-by":"publisher","first-page":"e874","DOI":"10.1212\/WNL.0000000000201289","article-title":"Longitudinal changes in blood biomarkers of clinical Alzheimer disease in a biracial population sample.","volume":"100","author":"Rajan","year":"2023","journal-title":"Neurology"},{"issue":"3","key":"joi240053r7","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.3233\/JAD-210673","article-title":"Association of APOE e4 and plasma p-tau181 with preclinical Alzheimer\u2019s disease and longitudinal change in hippocampus function.","volume":"85","author":"Salami","year":"2022","journal-title":"J Alzheimers Dis"},{"issue":"10","key":"joi240053r8","doi-asserted-by":"publisher","first-page":"4314","DOI":"10.1038\/s41380-022-01675-8","article-title":"Sex differences in plasma p-tau181 associations with Alzheimer\u2019s disease biomarkers, cognitive decline, and clinical progression.","volume":"27","author":"Tsiknia","year":"2022","journal-title":"Mol Psychiatry"},{"issue":"12","key":"joi240053r9","doi-asserted-by":"publisher","first-page":"5620","DOI":"10.1002\/alz.13318","article-title":"Longitudinal blood biomarker trajectories in preclinical Alzheimer\u2019s disease.","volume":"19","author":"Yakoub","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"7","key":"joi240053r10","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/s41591-022-01822-2","article-title":"Performance of plasma phosphorylated tau 181 and 217 in the community.","volume":"28","author":"Mielke","year":"2022","journal-title":"Nat Med"},{"issue":"6","key":"joi240053r11","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/alz.12466","article-title":"Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities.","volume":"18","author":"Syrjanen","year":"2022","journal-title":"Alzheimers Dement"},{"issue":"s1","key":"joi240053r12","doi-asserted-by":"publisher","first-page":"S405","DOI":"10.3233\/JAD-179911","article-title":"Metabolic dysfunction in Alzheimer\u2019s disease: from basic neurobiology to clinical approaches.","volume":"64","author":"Clarke","year":"2018","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"joi240053r13","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1001\/archneurol.2009.27","article-title":"The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged.","volume":"66","author":"Craft","year":"2009","journal-title":"Arch Neurol"},{"issue":"1","key":"joi240053r14","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/j.jalz.2013.12.004","article-title":"How does brain insulin resistance develop in Alzheimer\u2019s disease?","volume":"10","author":"De Felice","year":"2014","journal-title":"Alzheimers Dement"},{"issue":"14","key":"joi240053r15","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1001\/jama.2017.3090","article-title":"Association between midlife vascular risk factors and estimated brain amyloid deposition.","volume":"317","author":"Gottesman","year":"2017","journal-title":"JAMA"},{"issue":"11","key":"joi240053r16","doi-asserted-by":"publisher","first-page":"785","DOI":"10.7326\/M14-0737","article-title":"Diabetes in midlife and cognitive change over 20 years: a cohort study.","volume":"161","author":"Rawlings","year":"2014","journal-title":"Ann Intern Med"},{"issue":"23","key":"joi240053r17","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1016\/j.jacc.2021.04.035","article-title":"The ARIC (Atherosclerosis Risk In Communities) Study: JACC focus seminar 3\/8.","volume":"77","author":"Wright","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"joi240053r18","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"joi240053r19","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1161\/STROKEAHA.114.007847","article-title":"Vascular imaging abnormalities and cognition: mediation by cortical volume in nondemented individuals: atherosclerosis risk in communities-neurocognitive study.","volume":"46","author":"Knopman","year":"2015","journal-title":"Stroke"},{"issue":"12","key":"joi240053r20","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1212\/01.WNL.0000165985.97397.88","article-title":"Cerebral MRI findings and cognitive functioning: the Atherosclerosis Risk in Communities study.","volume":"64","author":"Mosley","year":"2005","journal-title":"Neurology"},{"issue":"1","key":"joi240053r21","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s13195-021-00944-y","article-title":"Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes.","volume":"13","author":"Marks","year":"2021","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"joi240053r22","doi-asserted-by":"publisher","first-page":"e252","DOI":"10.1212\/WNL.0000000000007767","article-title":"Plasma and CSF neurofilament light: relation to longitudinal neuroimaging and cognitive measures.","volume":"93","author":"Mielke","year":"2019","journal-title":"Neurology"},{"issue":"3","key":"joi240053r23","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging\u2014Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease.","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"3","key":"joi240053r24","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease.","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"key":"joi240053r26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.dadm.2015.12.002","article-title":"Mild cognitive impairment and dementia prevalence: the Atherosclerosis Risk in Communities Neurocognitive Study.","volume":"2","author":"Knopman","year":"2016","journal-title":"Alzheimers Dement (Amst)"},{"issue":"12","key":"joi240053r27","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1001\/jamaneurol.2022.3543","article-title":"Estimating the prevalence of dementia and mild cognitive impairment in the US: the 2016 Health and Retirement Study harmonized cognitive assessment protocol project.","volume":"79","author":"Manly","year":"2022","journal-title":"JAMA Neurol"},{"issue":"23","key":"joi240053r28","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1001\/jama.293.23.2892","article-title":"Apolipoprotein E and progression of chronic kidney disease.","volume":"293","author":"Hsu","year":"2005","journal-title":"JAMA"},{"issue":"19","key":"joi240053r29","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin c-based equations to estimate GFR without race.","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"joi240053r30","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1161\/01.ATV.14.7.1098","article-title":"Associations of lipoprotein cholesterols, apolipoproteins A-I and B, and triglycerides with carotid atherosclerosis and coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study.","volume":"14","author":"Sharrett","year":"1994","journal-title":"Arterioscler Thromb"},{"issue":"5","key":"joi240053r31","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1093\/ajcn\/36.5.936","article-title":"A short questionnaire for the measurement of habitual physical activity in epidemiological studies.","volume":"36","author":"Baecke","year":"1982","journal-title":"Am J Clin Nutr"},{"issue":"5","key":"joi240053r33","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1001\/jamaneurol.2023.0199","article-title":"Mitigating the associations of kidney dysfunction with blood biomarkers of Alzheimer disease by using phosphorylated tau to total tau ratios.","volume":"80","author":"Janelidze","year":"2023","journal-title":"JAMA Neurol"},{"key":"joi240053r34","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2023.1150510","article-title":"Effect of renal function on the diagnostic performance of plasma biomarkers for Alzheimer\u2019s disease.","volume":"15","author":"Zhang","year":"2023","journal-title":"Front Aging Neurosci"},{"issue":"3","key":"joi240053r35","doi-asserted-by":"publisher","first-page":"182","DOI":"10.7326\/0003-4819-153-3-201008030-00258","article-title":"Systematic review: factors associated with risk for and possible prevention of cognitive decline in later life.","volume":"153","author":"Plassman","year":"2010","journal-title":"Ann Intern Med"},{"issue":"10","key":"joi240053r36","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1002\/sim.4154","article-title":"On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data.","volume":"30","author":"Uno","year":"2011","journal-title":"Stat Med"},{"issue":"4","key":"joi240053r37","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1002\/alz.12787","article-title":"Confounding factors of Alzheimer\u2019s disease plasma biomarkers and their impact on clinical performance.","volume":"19","author":"Pichet Binette","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"12","key":"joi240053r38","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1002\/alz.12756","article-title":"The Alzheimer\u2019s Association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease.","volume":"18","author":"Hansson","year":"2022","journal-title":"Alzheimers Dement"},{"issue":"6","key":"joi240053r39","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/alz.12949","article-title":"Plasma A\u00df42\/A\u00df40A\u00df40 ratio is independent of renal function.","volume":"19","author":"Lehmann","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"4","key":"joi240053r40","doi-asserted-by":"publisher","first-page":"569","DOI":"10.14283\/jpad.2022.85","article-title":"Blood biomarkers from research use to clinical practice: what must be done? a report from the EU\/US CTAD task force.","volume":"9","author":"Angioni","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"issue":"3","key":"joi240053r41","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","article-title":"Plasma p-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia.","volume":"26","author":"Janelidze","year":"2020","journal-title":"Nat Med"},{"issue":"5","key":"joi240053r42","doi-asserted-by":"publisher","first-page":"e473","DOI":"10.1212\/WNL.0000000000201479","article-title":"Validity and performance of blood biomarkers for Alzheimer disease to predict dementia risk in a large clinic-based cohort.","volume":"100","author":"Planche","year":"2023","journal-title":"Neurology"},{"issue":"4","key":"joi240053r43","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/alz.12724","article-title":"Plasma A\u00df42\/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer\u2019s disease continuum: a cross-sectional and longitudinal study in the AIBL cohort.","volume":"19","author":"Chatterjee","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"8","key":"joi240053r44","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative accuracy of plasma phospho-tau217 for Alzheimer\u2019s disease vs other neurodegenerative disorders.","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"issue":"4","key":"joi240053r45","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease.","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"8","key":"joi240053r46","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1002\/alz.12511","article-title":"Alzheimer\u2019s disease biomarkers in Black and non-Hispanic White cohorts: a contextualized review of the evidence.","volume":"18","author":"Gleason","year":"2022","journal-title":"Alzheimers Dement"},{"key":"joi240053r25","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013","edition":"5th ed"},{"key":"joi240053r32","volume-title":"Physical Activity Guidelines for Americans","year":"2018","edition":"2nd ed"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2821670\/jama_lu_2024_oi_240053_1727974467.92971.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T11:30:02Z","timestamp":1728991802000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2821670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,15]]},"references-count":46,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2024,10,15]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2024.6619","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,15]]}}}